Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.20 Consensus PT from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have received a consensus rating of “Buy” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $16.20.

Several equities analysts recently commented on COYA shares. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. BTIG Research reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Tuesday. Lake Street Capital assumed coverage on Coya Therapeutics in a research note on Wednesday, July 9th. They issued a “buy” rating and a $16.00 target price on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, August 25th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in COYA. Jane Street Group LLC bought a new stake in Coya Therapeutics during the fourth quarter worth about $74,000. Northern Trust Corp raised its holdings in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares in the last quarter. CM Management LLC raised its holdings in shares of Coya Therapeutics by 25.0% during the 1st quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after buying an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC bought a new stake in Coya Therapeutics in the 1st quarter worth approximately $1,083,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Coya Therapeutics in the first quarter worth approximately $65,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Price Performance

NASDAQ:COYA opened at $5.87 on Tuesday. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24. The stock’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $5.97. The company has a market cap of $98.18 million, a P/E ratio of -4.73 and a beta of 0.20.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. On average, analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.